SYDNEY, June 30, 2021/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to provide an update on recent progress with its two pipeline assets, paxalisib and EVT801.

Key Points

• GBM AGILE pivotal study of paxalisib is recruiting ahead of expectations, with almost 25 sites now...